This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SUNDAY, Feb. 23, 2025 -- Fainting can be scary, but it's often harmless. Known medically as syncope, fainting happens when there’s not enough blood flow to the brain, causing a brief loss of consciousness. But how do you know if it's just a.
ABSTRACT Various substituted benzothiazole-thiadiazole-based ketones 4a-i and 6a-c were synthesized and characterized by the IR, NMR, and MS spectral data. The DFT study of the synthesized ketones 4 and 6 displayed matched configurations of their HOMO and LUMO, with the exception of the nitrophenyl derivatives, whose HOMO extended over the entire molecule.
By Steven J. Gonzalez & Allyson B. Mullen As the device industry is well aware, one of the greyest areas in device regulation (of which there are many) is determining when changes to a 510(k)-cleared device trigger the need for a new clearance. FDA requires a new 510(k) clearance when a modification to an existing 510(k)-cleared device (or other existing device subject to 510(k) requirements) could significantly affect the safety or effectiveness of the device.
The Cost-Effective Future of Medicine: Unpacking the Potential of Biosimilars As healthcare systems around the world continue to grapple with the rising costs of medication, a new solution is emerging: biosimilars. These highly similar versions of biologic medicines have the potential to revolutionize the way we approach healthcare costs, but how effective are they really?
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
In Part-1 , we learned about the importance of KUBEONE. Now, lets explore on demo part in this practical session will focus on creating High Availability Kubernetes Cluster on AWS using KUBEONE Setup KubeOne 1. Downloading KubeOne CREATE ec2 instance first with any type as suitable, then download KubeOne from below script. The below commands will be used to download KubeOne sudo apt-get update sudo apt-get -y install unzip curl -sfL [link] | sh The above script downloads the latest version of Ku
This article concludes Issue 05. We’ll see you in a few weeks for Issue 06! By Kamal Nahas Scientists had no antiretroviral drugs when the AIDS crisis began in 1981. Nearly 20,000 people died from AIDS during that first year, and the annual death toll rose to 1.6 million by 2004. After decades of research into therapies and preventive measures, though, global AIDS deaths have now fallen to about 600,000 annually.
This article concludes Issue 05. We’ll see you in a few weeks for Issue 06! By Kamal Nahas Scientists had no antiretroviral drugs when the AIDS crisis began in 1981. Nearly 20,000 people died from AIDS during that first year, and the annual death toll rose to 1.6 million by 2004. After decades of research into therapies and preventive measures, though, global AIDS deaths have now fallen to about 600,000 annually.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content